OBSV - ObsEva gets UK nod for uterine fibroids therapy

Swiss biopharmaceutical company ObsEva (NASDAQ:OBSV) on Tuesday said UK's drug regulator approved its antagonist Yselty for the treatment of uterine fibroids in adult women of reproductive age. OBSV stock rose 2.3% to $1.76 in after market trading. Uterine fibroids are non-cancerous growths of the uterus that often appear during childbearing years. The approval by the UK's Medicines and Healthcare Products Regulatory Agency for Yselty follows the European Commission's nod earlier in June. The application for Yselty in the U.S. is currently under review by the FDA. The regulator is set to make a decision on or before Sept. 13.

For further details see:

ObsEva gets UK nod for uterine fibroids therapy